CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.8611
-0.0189 (-2.15%)
At close: Sep 4, 2026, 4:00 PM EDT
0.8610
-0.0001 (-0.01%)
After-hours: Sep 4, 2026, 6:04 PM EDT
CytoMed Therapeutics Revenue
In the year 2025, CytoMed Therapeutics had annual revenue of 860.85K SGD with 71.02% growth. CytoMed Therapeutics had revenue of 410.16K in the half year ending December 31, 2025, with 83.51% growth.
Revenue (ttm)
860.85K SGD
Revenue Growth
+71.02%
P/S Ratio
15.22
Revenue / Employee
20,496 SGD
Employees
42
Market Cap
10.19M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 860.85K | 357.48K | 71.02% |
| Dec 31, 2024 | 503.37K | -4.36K | -0.86% |
| Dec 31, 2023 | 507.74K | 143.82K | 39.52% |
| Dec 31, 2022 | 363.91K | 250.07K | 219.67% |
| Dec 31, 2021 | 113.84K | 54.37K | 91.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 5.34M |
| Xenetic Biosciences | 3.26M |
| Vistagen Therapeutics | 2.50M |
| Daré Bioscience | 1.37M |
| Senti Biosciences Holdings | 55.00K |
| Kiora Pharmaceuticals | 20.00K |
| Azitra | 7.50K |
| Aprea Therapeutics | 5.19K |
GDTC News
- 5 months ago - CytoMed Therapeutics Annual report: H2 2025 - Filings
- 7 months ago - Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress - TheFly
- 7 months ago - Cytomed sees ‘enough resources’ to continue activites for ‘at least a year’ - TheFly
- 9 months ago - Cytomed Therapeutics enters into MoU with UMMC - TheFly
- 9 months ago - CytoMed completes acquisition of T cell technology of TC BioPharm - TheFly
- 10 months ago - Cytomed Therapeutics secures investment for subsidiary LongevityBank - TheFly
- 10 months ago - Cytomed Therapeutics chairman Peter Choo increases holdings to 21.95% - TheFly
- 10 months ago - Cytomed announces cash bid for potential acquisition of TC BioPharm - TheFly